Lytix Biopharma AS Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Net Income	-59.98	-94.27	-87.9	-56.07	-48.08	Upgrade
Depreciation & Amortization	1	0.92	0.96	0.92	0.45	Upgrade
Stock-Based Compensation	13.84	0.88	4.18	1.38	4.05	Upgrade
Other Operating Activities	-2.32	-1.5	-2.35	-1.35	-0.13	Upgrade
Change in Accounts Receivable	6.03	-0.34	-6.04	-1.06	-1.51	Upgrade
Change in Accounts Payable	-18.43	23.94	-4.83	3.55	0.61	Upgrade
Operating Cash Flow	-59.85	-70.37	-95.97	-52.63	-44.61	Upgrade
Capital Expenditures	-	-	-0.05	-0.15	-	Upgrade
Investment in Securities	-61.76	23.18	27.42	-50.61	-	Upgrade
Other Investing Activities	2.33	1.51	2.35	1.41	0.14	Upgrade
Investing Cash Flow	-59.43	24.69	29.73	-49.36	0.14	Upgrade
Long-Term Debt Repaid	-0.9	-0.85	-0.94	-0.83	-0.42	Upgrade
Net Debt Issued (Repaid)	-0.9	-0.85	-0.94	-0.83	-0.42	Upgrade
Issuance of Common Stock	-	161.3	-	0.13	225.21	Upgrade
Other Financing Activities	-0.01	-11.34	-0	-0.06	-11.49	Upgrade
Financing Cash Flow	-0.91	149.11	-0.94	-0.75	213.3	Upgrade
Miscellaneous Cash Flow Adjustments	0	-	-	-	-0	Upgrade
Net Cash Flow	-120.19	103.43	-67.19	-102.73	168.83	Upgrade
Free Cash Flow	-59.85	-70.37	-96.02	-52.78	-44.61	Upgrade
Free Cash Flow Margin	-	-632.05%	-2405.86%	-478.47%	-231.04%	Upgrade
Free Cash Flow Per Share	-0.88	-1.30	-2.40	-1.33	-1.34	Upgrade
Cash Interest Paid	0.01	0.01	0	0.06	0	Upgrade
Levered Free Cash Flow	-37.7	-34.62	-66.3	-36.49	-26.43	Upgrade
Unlevered Free Cash Flow	-37.57	-34.54	-66.27	-36.4	-26.39	Upgrade
Change in Working Capital	-12.39	23.6	-10.87	2.5	-0.9	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.